Acitretin

Generic Name
Acitretin
Brand Names
Soriatane
Drug Type
Small Molecule
Chemical Formula
C21H26O3
CAS Number
55079-83-9
Unique Ingredient Identifier
LCH760E9T7
Background

An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.

Indication

For the treatment of severe psoriasis in adults.

Associated Conditions
Keratinization disorders, Severe Psoriasis
Associated Therapies
-

Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-03-06
Last Posted Date
2014-07-24
Lead Sponsor
Innovaderm Research Inc.
Target Recruit Count
9
Registration Number
NCT01545284
Locations
🇨🇦

Windsor Clinical Research Inc., Windsor, Ontario, Canada

🇨🇦

Innovaderm Research Inc., Montreal, Quebec, Canada

Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2

First Posted Date
2011-09-29
Last Posted Date
2011-09-29
Lead Sponsor
Ministry of Health, China
Target Recruit Count
720
Registration Number
NCT01443338
Locations
🇨🇳

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

Phase 4
Withdrawn
Conditions
First Posted Date
2011-02-18
Last Posted Date
2013-01-16
Lead Sponsor
University of Pittsburgh
Registration Number
NCT01299220
Locations
🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Alzheimer's Disease Acitretin Medication

Phase 2
Completed
Conditions
Interventions
First Posted Date
2010-03-02
Last Posted Date
2018-02-05
Lead Sponsor
K. Lieb
Target Recruit Count
22
Registration Number
NCT01078168
Locations
🇩🇪

Department of psychiatry and psychotherapy, University medical center of the Johannes Gutenberg-University Mainz, Mainz, Rheinland-Pfalz, Germany

🇩🇪

Universität Rostock, Rostock, Germany

Dose Ranging Study to Assess the Efficacy and Safety of Acitretin in Severe Plaque Type Psoriasis

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-12-24
Last Posted Date
2009-12-24
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
61
Registration Number
NCT01039142
Locations
🇮🇳

Post Graduate institute Of Medical Education and Research, Chandigarh, India

Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis

First Posted Date
2009-07-09
Last Posted Date
2012-04-09
Lead Sponsor
Pfizer
Target Recruit Count
60
Registration Number
NCT00936065
Locations
🇰🇷

Pfizer Investigational Site, Seoul, Korea, Republic of

Evaluation of the Efficacy of Acitretin Therapy for Nail Psoriasis

Phase 4
Completed
Conditions
First Posted Date
2008-07-28
Last Posted Date
2008-07-28
Lead Sponsor
Istituti Fisioterapici Ospitalieri
Target Recruit Count
36
Registration Number
NCT00723437
Locations
🇮🇹

Department of Dermatology University of Bologna, Bologna, Italy

Acitretin in Preventing Skin Cancer in Patients at High Risk for Skin Cancer

Not Applicable
Completed
Conditions
First Posted Date
2008-03-26
Last Posted Date
2011-05-16
Lead Sponsor
Mayo Clinic
Target Recruit Count
130
Registration Number
NCT00644384

Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-11-06
Last Posted Date
2019-03-20
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Target Recruit Count
40
Registration Number
NCT00395941
Locations
🇮🇳

PGIMER, Chandigarh, India

Acitretin and Etanercept in Psoriasis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-09-12
Last Posted Date
2015-02-16
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
10
Registration Number
NCT00156247
© Copyright 2024. All Rights Reserved by MedPath